Abstract
RNA interference (RNAi) can be applied to human cancer cells by using small interfering RNAs (siRNAs) for inhibition of activated oncogenes' expression with the amelioration of several malignant phenotypes such as uncontrolled cell growth, resistance to apoptosis or invasive ability. siRNAs with high specificity to active oncogenes (e.g. missense mutation, gene rearrangement or over-expression) could be alternatives for molecular target drugs although several issues such as in vivo siRNA delivery methods, off-target effects, interferon responses require to be solved.
